Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with hepatitis A and B vaccines.

Jeffrey P Davis1

  • 1Bureau of Communicable Diseases and Preparedness, Wisconsin Division of Public Health, Madison, Wisconsin 53702, USA. davisjp@dhfs.state.wi.us

The American Journal of Medicine
|November 8, 2005
PubMed
Summary

Vaccines for hepatitis A (HAV) and hepatitis B (HBV) have significantly reduced infections, but further reductions are possible. Expanding adult vaccination recommendations can further decrease viral hepatitis burden.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Brand-specific rates of pertussis disease among Wisconsin children given 1-4 doses of pertussis Vaccine, 2010-2014.

Vaccine·2020
Same author

Identification of compound causing yellow bone discoloration following alpha-glycosyl isoquercitrin exposure in Sprague-Dawley rats.

Archives of toxicology·2020
Same author

Enhanced Arboviral Surveillance to Increase Detection of Jamestown Canyon Virus Infections, Wisconsin, 2011-2016.

The American journal of tropical medicine and hygiene·2018
Same author

Non-mumps Viral Parotitis During the 2014-2015 Influenza Season in the United States.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2018
Same author

Influenza-Associated Parotitis During the 2014-2015 Influenza Season in the United States.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2018
Same author

Proposal to reclassify Ehrlichia muris as Ehrlichia muris subsp. muris subsp. nov. and description of Ehrlichia muris subsp. eauclairensis subsp. nov., a newly recognized tick-borne pathogen of humans.

International journal of systematic and evolutionary microbiology·2017

Area of Science:

  • Hepatology
  • Immunology
  • Vaccinology

Background:

  • Hepatitis A virus (HAV) and hepatitis B virus (HBV) infections pose significant public health challenges.
  • Decades of research have led to the development of effective vaccines for both HAV and HBV.
  • Vaccine development progressed from plasma-derived to recombinant hepatitis B vaccines, and HAV vaccines were introduced later.

Purpose of the Study:

  • To review clinical trial and real-world data on hepatitis A and B vaccines.
  • To assess the impact of vaccination on reducing HAV and HBV infection incidence.
  • To recommend expanding vaccination strategies for broader public health benefit.

Main Methods:

  • Review of clinical trial data and post-licensure experience with HAV and HBV vaccines.
  • Analysis of national vaccination recommendations and their effect on infection rates.
  • Evaluation of vaccine efficacy in diverse populations, including those with chronic liver disease, HIV, or on hemodialysis.

Main Results:

  • Hepatitis A and B vaccines have led to substantial decreases in hepatitis-related morbidity and mortality.
  • Despite reductions, vaccine-preventable hepatitis infections continue to occur.
  • Combination vaccines offer convenience and have been integrated into vaccination schedules.

Conclusions:

  • Current vaccination strategies have been highly successful but can be improved.
  • Universal adult vaccination for hepatitis A and B is recommended to further reduce disease burden.
  • Continued surveillance and updated recommendations are crucial for controlling viral hepatitis.

Related Experiment Videos